Comparison of silicone versus polyurethane ureteral stents: a prospective controlled study.
Polyurethane
Quality of life
Silicone
Stent-related symptoms
Ureteral stent
Journal
BMC urology
ISSN: 1471-2490
Titre abrégé: BMC Urol
Pays: England
ID NLM: 100968571
Informations de publication
Date de publication:
03 Feb 2020
03 Feb 2020
Historique:
received:
10
06
2019
accepted:
20
01
2020
entrez:
5
2
2020
pubmed:
6
2
2020
medline:
20
11
2020
Statut:
epublish
Résumé
Approximately 80% of patients with indwelling ureteral stents experience stent related symptoms (SRS). We believe SRS can be reduced through altering the composition of ureteral stents to a less firm material. Therefore, we aim to compare modern silicone and polyurethane ureteral stents in terms of SRS intensity and safety. From June 2018 to October 2018, patients from two distinct clinical centers were prospectively enrolled in the study and stratified (non-randomly) into either control group A, patients who received polyurethane stents (Rüsch, Teleflex), or experimental group B, patients who received silicone stents (Cook Medical). Each participant completed a survey 1 h after stent insertion, in the middle of the stent dwelling period, and before stent removal or ureteroscopy noting body pain and overactive bladder via the visual analog scale pain (VASP) and overactive bladder (OAB) awareness tool, respectively. Additionally, successfulness of stent placement, hematuria, number of unplanned visits, and stent encrustation rates were assessed within each group. A total of 50 patients participated in the study, control group A consisted of 20 patients and experimental group B consisted of 30 patients. Participants in group B, silicone ureteral stents, demonstrated significantly lower mean values of VASP 2 weeks prior to stent removal and promptly before stent removal (p = 0.023 and p = 0.014, respectively). No other comparisons between the two groups were statistically significant. Compared to polyurethane ureteral stents, silicone ureteral stents are associated with lower body pain intensity assessed by VASP 2 weeks before stent removal and at the time of stent removal. Current Controlled Trials NCT04000178. Retrospectively registered on June 26, 2019.
Sections du résumé
BACKGROUND
BACKGROUND
Approximately 80% of patients with indwelling ureteral stents experience stent related symptoms (SRS). We believe SRS can be reduced through altering the composition of ureteral stents to a less firm material. Therefore, we aim to compare modern silicone and polyurethane ureteral stents in terms of SRS intensity and safety.
METHODS
METHODS
From June 2018 to October 2018, patients from two distinct clinical centers were prospectively enrolled in the study and stratified (non-randomly) into either control group A, patients who received polyurethane stents (Rüsch, Teleflex), or experimental group B, patients who received silicone stents (Cook Medical). Each participant completed a survey 1 h after stent insertion, in the middle of the stent dwelling period, and before stent removal or ureteroscopy noting body pain and overactive bladder via the visual analog scale pain (VASP) and overactive bladder (OAB) awareness tool, respectively. Additionally, successfulness of stent placement, hematuria, number of unplanned visits, and stent encrustation rates were assessed within each group.
RESULTS
RESULTS
A total of 50 patients participated in the study, control group A consisted of 20 patients and experimental group B consisted of 30 patients. Participants in group B, silicone ureteral stents, demonstrated significantly lower mean values of VASP 2 weeks prior to stent removal and promptly before stent removal (p = 0.023 and p = 0.014, respectively). No other comparisons between the two groups were statistically significant.
CONCLUSIONS
CONCLUSIONS
Compared to polyurethane ureteral stents, silicone ureteral stents are associated with lower body pain intensity assessed by VASP 2 weeks before stent removal and at the time of stent removal.
TRIAL REGISTRATION
BACKGROUND
Current Controlled Trials NCT04000178. Retrospectively registered on June 26, 2019.
Identifiants
pubmed: 32013936
doi: 10.1186/s12894-020-0577-y
pii: 10.1186/s12894-020-0577-y
pmc: PMC6998278
doi:
Substances chimiques
Polyurethanes
0
Silicones
0
Banques de données
ClinicalTrials.gov
['NCT04000178']
Types de publication
Comparative Study
Controlled Clinical Trial
Journal Article
Multicenter Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
10Références
Urol J. 2019 Jun 17;16(3):307-311
pubmed: 30120759
J Urol. 1978 Dec;120(6):678-81
pubmed: 731804
Eur Urol. 1995;28(1):1-5
pubmed: 8521886
Int J Antimicrob Agents. 2002 Jun;19(6):507-10
pubmed: 12135841
J Urol. 2005 Dec;174(6):2303-6
pubmed: 16280829
J Biomed Mater Res. 1997 Summer;38(2):87-93
pubmed: 9178735
Acad Emerg Med. 2001 Dec;8(12):1153-7
pubmed: 11733293
J Urol. 1967 May;97(5):840-4
pubmed: 6025928
BJU Int. 2018 Nov;122(5):866-872
pubmed: 29802800
BJU Int. 2013 Jan;111(1):101-5
pubmed: 22578110
Cent European J Urol. 2017;70(3):270-274
pubmed: 29104790
Indian J Urol. 2009 Oct-Dec;25(4):455-60
pubmed: 19955667
J Urol. 1991 Apr;145(4):719-22
pubmed: 2005686
Urology. 2002 Apr;59(4):511-6
pubmed: 11927301
Urol Res. 2012 Dec;40(6):763-7
pubmed: 22899382
J Urol. 2019 Jul;202(1):164-170
pubmed: 30829132
J Urol. 1989 Mar;141(3):510-2
pubmed: 2918584
J Urol. 2003 Mar;169(3):1065-9; discussion 1069
pubmed: 12576847
Urology. 2018 May;115:3-7
pubmed: 29545037
Clin Radiol. 2002 Jan;57(1):59-62
pubmed: 11798204
Adv Ther. 2005 Jul-Aug;22(4):381-94
pubmed: 16418145
BMC Urol. 2016 Nov 15;16(1):66
pubmed: 27846839
J Endourol. 2003 May;17(4):195-9
pubmed: 12816579
J Endourol. 1998 Dec;12(6):493-500
pubmed: 9895250
Biostatistics. 2009 Jan;10(1):1-2
pubmed: 18550565
Biomaterials. 1997 Oct;18(20):1379-83
pubmed: 9363338
J Endourol. 2010 Feb;24(2):191-8
pubmed: 20073560
Med Devices (Auckl). 2011;4:11-5
pubmed: 22915925